Evaluation of healthcare resource utilisation and costs associated with anogenital warts in South Africa
DOI:
https://doi.org/10.7196/Keywords:
Anogenital warts, HPV, Anogenital diseases, Healthcare costs, Healthcare resource utilisation, South AfricaAbstract
Background. Human papilloma virus (HPV), the most prevalent sexually transmitted infection worldwide, and in particular HPV 6 and 11, contribute to >90% of anogenital warts (AGW) cases, and high-risk HPV serotypes cause >95% of cervical cancers in South Africa (SA). The healthcare resource utilisation (HCRU) and costs related to AGW in SA remain poorly understood, in both the public and private sectors.
Objective. To assess the HCRU patterns and associated treatment costs for AGW across the public and private sectors.
Methods. A descriptive, questionnaire-based study was conducted, involving 50 subject matter experts (SMEs) from SA: 24 from the private sector and 26 from the public sector. The study explored resource use, treatment patterns and cost estimation based on SME responses.
Results. Findings revealed that public-sector SMEs treated a larger volume of AGW patients per month (1 - 300) than private-sector SMEs (0 - 20). Most AGW patients were female, comprising 78% in the public sector and 72% in the private sector. The occurrence of AGW was higher in the public sector, ranging between 21.4% and 34.4%, while in the private sector, the occurrence ranged from 13.1% to 23.2%. The weighted cost per patient per episode was higher for females than males in both sectors. In the private sector, costs were ZAR22 482 for females and ZAR17 812 for males, while in the public sector, costs were ZAR19 220 for females and ZAR14 271 for males. The higher costs for females were driven by invasive diagnostic procedures, including vulvar colposcopy and biopsy, and a higher frequency of medical visits (2.0 - 4.4 visits in the public sector). Recurrence rates of AGW were reported at 37.6% in the private sector and 43.9% in the public sector. The total estimated treatment cost of AGW was notably higher in the public sector for both males (ZAR93.6 - ZAR138.5 billion) and females (ZAR135.2 - ZAR207.7 billion), compared with the private sector (males: ZAR11.0 - ZAR19.4 billion; females: ZAR16.7 - ZAR28.3 billion). Female patients experienced a higher burden of diagnosis, recurrence and complications than males.
Conclusion. AGW imposes a substantial burden on SA’s healthcare system, particularly in the public sector, where female patients face significant costs and complications. The use of a quadrivalent or nonavalent HPV vaccine, rather than a bivalent vaccine, could reduce the impact of AGW and its associated healthcare demands.
References
1. Fowler JR, Maani EV, Dunton CJ, et al. Cervical Cancer. Treasure Island (FL): StatPearls Publishing, 2022. https://www.ncbi.nlm.nih.gov/books/NBK431093/ (accessed 19 August 2025).
2. Kombe AJ, Li B, Zahid A, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Pub Health 2021;8:552028. https:// doi.org/10.3389/fpubh.2020.552028
3. Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014;41(11):660-664. https://doi.org/10.1097/ olq.0000000000000193
4. Brianti P, de Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol 2017;40(2):80-85.
5. Dareng EO, Adebamowo SN, Famooto A, et al. Prevalence and incidence of genital warts and cervical human papillomavirus infections in Nigerian women. BMC Infect Dis 2019;19(1):1-10. https://doi. org/10.1186/s12879-018-3582-y
6. Meites E, Gee J, Unger E, et al. Human papillomavirus. Chapter 11. In: Hall E, Wodi AP, Hamborsky J, et al, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2021:165-176.
7. Looker KJ, Rönn MM, Brock PM, et al. Evidence of synergistic relationships between HIV and human papillomavirus (HPV): Systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc 2018;21(6):e25110. https://doi.org/10.1002/jia2.25110
8. Van Aar F, Mooij SH, van der Sande MA, et al. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS 2013;27(18):2921-2931. https://doi. org/10.1097/01.aids.0000432541.67409.3c
9. Human Sciences Research Council. SABSSM VI shows prevalence peak shift to older people. Pretoria: HSRC, 2023. https://hsrc.ac.za/news/research-excellence/sabssm-vi-shows-prevalence-peak-shift-to- older-people/ (accessed 19 August 2025).
10. Govender K, Beckett S, Reddy T, et al. Association of HIV intervention uptake with HIV prevalence in adolescent girls and young women in South Africa. JAMA Netw Open 2022;5(4):e228640. https://doi. org/10.1001/jamanetworkopen.2022.8640
11. Banura C, Mirembe FM, Orem J, Mbonye AK, Kasasa S, Mbidde EK. Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: A systematic review and meta-analysis. Infect Agent Cancer 2013;8(1):27. https://doi.org/10.1186/1750-9378-8-27
12. Van der Weele P, Breeuwsma M, Donken R, et al. Effect of the bivalent HPV vaccine on viral load of vaccine and non-vaccine HPV types in incident clearing and persistent infections in young Dutch females. PLoS ONE 2019;14(3):e0212927. https://doi.org/10.1371/journal.pone.0212927
13. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. PharmacoEconomics 2005;23(11):1107 - 1122. https://doi.org/10.2165/00019053- 200523110-00004
14. Castellsague X, Cohet C, Puig-Tintore LM, et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Pub Health 2009;19(1):106-110. https://doi.org/10.1093/eurpub/ckn127
15. Chikandiwa A, Kelly H, Sawadogo B, et al. Prevalence, incidence and correlates of low risk HPV infection and anogenital warts in a cohort of women living with HIV in Burkina Faso and South Africa. PLoS ONE 2018;13(5):e0196018. https://doi.org/10.1371/journal.pone.0196018
16. National Department of Health, South Africa. Uniform Patient Fee Schedule. Pretoria: NDoH, 2023. https://www.health.gov.za/uniform-patient-fee-schedule/ (accessed 21 September 2023).
17. Government Employees Medical Scheme. Government Employees Medical Scheme preventative care and screening benefit. GEMS, 2023. https://www.gems.gov.za/Healthcare-Providers/Preventative- screening (accessed 21 September 2023).
18. Mediclinic Southern Africa. MCSA private tariff schedule (South Africa). Mediclinic, 1 Jan 2023.
https://www.mediclinic.co.za/en/corporate/private-fixed-fees/all-private-fixed-fee-products.html
(accessed 21 September 2023).
19. Council for Medical Schemes. The ABC of PMBs 2010-2011. Pretoria: CMS, 2010. https://www.
medicalschemes.com/files (accessed 21 September 2023).
20. Medicineprices.org.za. What should your medicines cost? https://medicineprices.org.za/ (accessed 21
September 2023).
21. Statistics South Africa. South Africa’s people. Pretoria: Stats SA, 2023. https://www.gov.za/about-sa/
south-africas-people (accessed 21 September 2023).
22. Worldometers. South Africa population. Worldometers, 2023. https://www.worldometers.info/world-
population/south-africapopulation/ (accessed 21 September 2023).
23. Council for Medical Schemes. Annual report 2021/22. Pretoria: CMS, 2022. https://www.medicalschemes.
co.za/publications/#2009-3631-wpfd-2021-22-annual-report (accessed 21 September 2023).
24. Rensburg R. Healthcare in South Africa: How inequity is contributing to inefficiency. The Conversation South Africa 2021. https://theconversation.com/healthcare-in-south-africa-how-
inequity-is-contributing-to-inefficiency-163753 (accessed 8 April 2026).
25. Ranchod S, Adams C, Burger R, et al. South Africa’s hospital sector: Old divisions and new developments. S Afr Health Rev 2017;1:101-110. http://hdl.handle.net/10019.1/107608 (accessed 8 April 2026).
26. Guerra FM, Rosella LC, Dunn S, et al. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: A retrospective longitudinal population-based study. BMJ Open 2016;6(3):e009914. https://doi.org/10.1136/ bmjopen-2015-009914
27. Dinh T-H, Sternberg M, Dunne EF, et al. Genital warts among 18- to 59-year-olds in the United States. National Health and Nutrition Examination Survey, 1999-2004. Sexually Transmitted Dis 2008;35(4):357-360. https://doi.org/10.1097/OLQ.0b013e3181632d61
28. Shin HR, Franceschi S, Vaccarella S, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190(3):468-476. https://doi.org/10.1086/421279
29. Lekoane KMB, Kuupiel D, Mashamba-Thompson TP, et al. The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: Scoping review. Syst Rev 2020;9(1):1-13. https:// doi.org/10.1186/s13643-020-01354-1
30. Wandera SO, Kwagala B, Maniragaba F. Prevalence and determinants of recent HIV testing among older persons in rural Uganda: A cross-sectional study. BMC Public Health 2020;20:1-10. https://doi. org/10.1186/s12889-020-8193-z
31. Gilson R, Nugent D, Werner RN, et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2020;34(8):1644-1653. https://doi.org/10.1111/jdv.16522
32. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004;70(12):2335-2342.
33. Merito M, Largeron N, Cohet C, et al. Treatment patterns and associated costs for genital warts in Italy.
Curr Med Res Opin 2008;24(11):3175-3183. https://doi.org/10.1185/03007990802485694
34. Pirotta M, Stein AN, Conway EL, et al. Genital warts incidence and healthcare resource utilisation in
Australia. Sexual Transmit Infect 2010;86(3):181-186. https://doi.org/10.1136/sti.2009.040188
35. Raymakers AJ, Sadatsafavi M, Marra F, et al. Economic and humanistic burden of external genital warts. Pharmacoeconomics 2012;30(1):1-16. https://doi.org/10.2165/11591170-000000000-00000
36. Bennacef AC, Khodja AA, Abou-Bekr FA, et al. Costs and resource use among patients with cervical
cancer, cervical intraepithelial neoplasia, and genital warts in Algeria. J Health Econ Outcomes Res
2022;9(1):31-38. https://doi.org/10.36469/jheor.2022.31049
37. Berrada M, Holl R, Ndao T, et al. Healthcare resource utilisation and costs associated with anogenital
warts in Morocco. Infect Agent Cancer 2021;16(1):64. https://doi.org/10.1186/s13027-021-00403-1 38. Chesson HW, Ekwueme DU, Saraiya M, et al. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Vaccine 2012;30(42):6016-6019. https://doi.org/10.1016/j.vaccine.2012.07.056
39. Lipsy RJ. Assessing the short-term and long-term burden of illness in cervical cancer. Am J Manag Care 2008;14(6 Suppl 1):S177-S184. https://www.ajmc.com/view/jun08-3382ps177-s184 (accessed
8 April 2026).
40. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human
papillomavirus vaccine with incidence of condyloma. JAMA 2014;311(6):597-603. https://doi.
org/10.1001/jama.2014.95
41. Herweijer E, Sundström K, Ploner A, et al. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Int J Cancer 2016;138(12):2867-2874. https://doi.org/10.1002/ijc.30035
Downloads
Published
Issue
Section
License
Copyright (c) 2026 S Mutambirwa, M H Botha, B M Mulaudzi, M S Mabenge, T Gaqana
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
